Study Examines Clinical Trial Volunteers' Perceptions of Investigators' Financial Interests
Investigators' financial interests have little effect on potential clinical trial participants.
NY-April 3, 2008-The Journal of General Internal Medicine published a new study online that takes a look at how disclosing the financial interests of investigators affects the willingness of potential trial volunteers to participate. Generally, the research-compiled by Duke University School of Medicine, Johns Hopkins Berman Institute of Bioethics, Johns Hopkins School of Medicine, and Wake Forest School of Medicine and School of Law, and funded by the National Institutes of Health-showed that potential subjects' desires to volunteer were generally unaffected by learning about an investigator's financial interest, although some volunteers' levels of trust in the investigator was influenced upon the reveal of financial interests. To read more, visit www.springerlink.com/content/jn8914455w236040.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
